Status: Not yet recruiting
The Holistic Study
This study is a phase 3 study where eligible patients will be randomized 1:1 to one of two treatment strategies: receiving a thrombopoietin receptor agonist (Avatrombopag), or anti-CD20 (Rituximab).
Participants needed: 220
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Ostfold Hospital TrustUpdated: Sep 9, 2025
Eligibility criteria
Male or female aged ≥18 years. [+3]
Previous treatment for ITP with: Rituximab, other immune suppressants (including... [+14]